INT101068

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.03
First Reported 2002
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 27
Total Number 27
Disease Relevance 17.67
Pain Relevance 3.45

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (CDCP1) plasma membrane (CDCP1)
Anatomy Link Frequency
platelet 2
stem cell 1
pole 1
CDCP1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 22 99.36 Very High Very High Very High
Inflammation 75 98.84 Very High Very High Very High
cINOD 28 98.72 Very High Very High Very High
Neuropathic pain 2 98.16 Very High Very High Very High
Osteoarthritis 103 98.04 Very High Very High Very High
Inflammatory mediators 7 95.92 Very High Very High Very High
headache 2 93.16 High High
Central nervous system 13 87.60 High High
pruritus 5 82.88 Quite High
Dorsal horn neuron 1 82.04 Quite High
Disease Link Frequency Relevance Heat
Disease 195 100.00 Very High Very High Very High
Death 89 99.64 Very High Very High Very High
Pain 24 99.36 Very High Very High Very High
INFLAMMATION 89 98.84 Very High Very High Very High
Liver Cancer 8 98.64 Very High Very High Very High
Mesothelioma 47 98.52 Very High Very High Very High
Colon Cancer 11 98.46 Very High Very High Very High
Cancer 368 98.20 Very High Very High Very High
Neuropathic Pain 2 98.16 Very High Very High Very High
Osteoarthritis 105 98.04 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Imatinib mesylate (IM), is a selective and competitive inhibitor of tyrosine kinases, including BCR-ABL, ABL, KIT, and the platelet-derived growth factor receptors (PDGF-R).
Negative_regulation (inhibitor) of kinases in platelet
1) Confidence 0.03 Published 2003 Journal J. Exp. Clin. Cancer Res. Section Abstract Doc Link 16767900 Disease Relevance 0.58 Pain Relevance 0
Dasatinib, a potent inhibitor of src family kinases, inhibits migration and invasion of mesothelioma in preclinical models [47].
Negative_regulation (inhibitor) of kinases associated with mesothelioma
2) Confidence 0.03 Published 2008 Journal Curr Treat Options Oncol Section Body Doc Link PMC2782121 Disease Relevance 0.59 Pain Relevance 0.05
We report that in human colorectal carcinoma cells NSAIDs stimulated the three families of MAPK, extracellular regulated kinases, c-Jun N-terminal kinases, p38 MAPK and that this stimulation is prevented by N-acetyl cysteine.
Negative_regulation (prevented) of kinases associated with colon cancer and cinod
3) Confidence 0.03 Published 2002 Journal Biochem. Pharmacol. Section Abstract Doc Link 11841790 Disease Relevance 0.42 Pain Relevance 0.72
We report that in human colorectal carcinoma cells NSAIDs stimulated the three families of MAPK, extracellular regulated kinases, c-Jun N-terminal kinases, p38 MAPK and that this stimulation is prevented by N-acetyl cysteine.
Negative_regulation (prevented) of kinases associated with colon cancer and cinod
4) Confidence 0.03 Published 2002 Journal Biochem. Pharmacol. Section Abstract Doc Link 11841790 Disease Relevance 0.42 Pain Relevance 0.72
It is a feature of cellular transformation, accompanied by the deregulation of Cyclin dependent Kinases (Cdks) involved in the control of the cell cycle, check points, and apoptosis which has a crucial role in the growth of both normal and malignant cells [24,25].
Negative_regulation (deregulation) of Kinases associated with malignant neoplastic disease and apoptosis
5) Confidence 0.02 Published 2005 Journal BMC Clin Pharmacol Section Body Doc Link PMC1090568 Disease Relevance 0.78 Pain Relevance 0.07
Sorafenib (Nexavar, Bayer) is a molecular inhibitor of several tyrosine kinases.
Negative_regulation (inhibitor) of kinases
6) Confidence 0.01 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2974748 Disease Relevance 1.35 Pain Relevance 0.04
Inhibition of multiple kinases has been shown to attenuate inflammatory and neuropathic pain in different animal models.
Negative_regulation (Inhibition) of kinases associated with inflammation and neuropathic pain
7) Confidence 0.01 Published 2007 Journal Handb Exp Pharmacol Section Abstract Doc Link 17087130 Disease Relevance 1.16 Pain Relevance 0.83
Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c-Kit, the receptor for stem cell factor.
Negative_regulation (inhibitor) of kinases in stem cell
8) Confidence 0.01 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2855702 Disease Relevance 0.99 Pain Relevance 0.12
Imatinib (Gleevec, Novartis, Basel, Switzerland) is a recently developed selective inhibitor of several tyrosine kinases including KIT.
Negative_regulation (inhibitor) of kinases
9) Confidence 0.01 Published 2008 Journal World J Surg Oncol Section Body Doc Link PMC2567321 Disease Relevance 0.95 Pain Relevance 0
Another phase 3 trial, which is enrolling more than 1,200 patients in this setting and has just finished recruitment, is investigating letrozole in combination with lapatinib, a dual inhibitor of HER2 and HER1 tyrosine kinases [84].
Negative_regulation (inhibitor) of kinases
10) Confidence 0.01 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001217 Disease Relevance 0.68 Pain Relevance 0
Sunitinib is an inhibitor of multiple members of the split-domain family of receptor tyrosine kinases (RTKs) especially those related to angiogenesis.
Negative_regulation (inhibitor) of kinases
11) Confidence 0.01 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727778 Disease Relevance 0.69 Pain Relevance 0
This phenomenon may limit the impact of exclusively targeting EGFR and c-erbB2 proteins, and may explain the acquired resistance to anticancer drugs that inhibit receptor tyrosine kinases [61].
Negative_regulation (inhibit) of kinases
12) Confidence 0.01 Published 2010 Journal Diagn Pathol Section Body Doc Link PMC2859381 Disease Relevance 0.52 Pain Relevance 0
Specific inhibitors of the mitogen-activated protein kinases (MAPKs) p38 (SB203580) and c-Jun N-terminal kinase (SP600125), but not of extracellular signal-regulated kinase (PD98059), prevented IL-1-induced downregulation of PPAR?
Negative_regulation (inhibitors) of kinases
13) Confidence 0.01 Published 2007 Journal Arthritis Res Ther Section Abstract Doc Link PMC1906809 Disease Relevance 0.79 Pain Relevance 0.43
The effect of ET-1 on MMP-13 production was more sensitive to the inhibitors of protein kinases than on MMP-1 production.
Negative_regulation (inhibitors) of kinases
14) Confidence 0.01 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1065327 Disease Relevance 0.53 Pain Relevance 0.15
Dasatinib is a potent inhibitor of multiple oncogenic kinases including Src, cKIT, BCR-ABL, PDGFR, and ephrin A.
Negative_regulation (inhibitor) of kinases
15) Confidence 0.01 Published 2010 Journal Head Neck Oncol Section Body Doc Link PMC2868849 Disease Relevance 0.64 Pain Relevance 0
In these experiments inhibition of Src kinases in originally cetuximab-resistant cell lines resulted in a regaining of sensitivity against cetuximab, indicating a close interaction between Src and EGF-R regarding the processes causing cetuximab resistance in tumour cells [27].
Negative_regulation (inhibition) of kinases associated with cancer
16) Confidence 0.01 Published 2010 Journal Head Neck Oncol Section Body Doc Link PMC2868849 Disease Relevance 0.66 Pain Relevance 0
Indeed, this molecule is probably not specific to PI3K at the concentration that was used, and could perhaps inhibit other kinases, such as PI4K [29,30], which is probably implicated in limiting the LPS effect.
Negative_regulation (inhibit) of kinases
17) Confidence 0.01 Published 2010 Journal J Inflamm (Lond) Section Body Doc Link PMC2819999 Disease Relevance 0.22 Pain Relevance 0
Mixed-lineage kinase 3 (MLK-3, a kinase of the family controlling MAP kinases activity) inhibition, can cause mitotic arrest by a mechanism involving disruption of microtubule formation and spindle pole assembly [30].
Negative_regulation (inhibition) of kinases in pole
18) Confidence 0.01 Published 2008 Journal BMC Complement Altern Med Section Body Doc Link PMC2613870 Disease Relevance 0.61 Pain Relevance 0.03
Imatinib mesylate (IM) (Gleevec®, Novartis), a 2-phenylaminopyrimidine derivative, is a potent inhibitor of targeted protein tyrosine kinases, including BCR-ABL, c-kit, and platelet-derived growth factor receptor (PDGF-R), and was developed in the mid-1990s against a background of some uncertainty.1–3 The drug appears to work principally by occupying the ATP binding site of the BCR-ABL oncoprotein and thereby preventing phosphorylation of the substrate and interrupting contact with the effector protein.
Negative_regulation (inhibitor) of kinases in platelet
19) Confidence 0.01 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC3010822 Disease Relevance 0.21 Pain Relevance 0
A number of small molecule inhibitors of multiple kinases have entered the clinic.
Negative_regulation (inhibitors) of kinases
20) Confidence 0.00 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2242654 Disease Relevance 0.57 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox